Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBT: 2009-2024

Historic EBT for Amicus Therapeutics (FOLD) over the last 16 years, with Dec 2024 value amounting to -$28.8 million.

  • Amicus Therapeutics' EBT rose 405.14% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 107.29%. This contributed to the annual value of -$28.8 million for FY2024, which is 80.84% up from last year.
  • Per Amicus Therapeutics' latest filing, its EBT stood at -$28.8 million for FY2024, which was up 80.84% from -$150.1 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' EBT registered a high of -$28.8 million during FY2024, and its lowest value of -$274.3 million during FY2020.
  • Its 3-year average for EBT is -$140.3 million, with a median of -$150.1 million in 2023.
  • In the last 5 years, Amicus Therapeutics' EBT dropped by 0.20% in 2022 and then surged by 80.84% in 2024.
  • Amicus Therapeutics' EBT (Yearly) stood at -$274.3 million in 2020, then rose by 11.92% to -$241.6 million in 2021, then dropped by 0.20% to -$242.0 million in 2022, then skyrocketed by 37.98% to -$150.1 million in 2023, then spiked by 80.84% to -$28.8 million in 2024.